Vericel reported 2Q22 orthopedic sales of $28.6 million, +7.9% vs. 2Q21. The company generated the highest MACI revenue total of any non-4Q since launch.
The company beat a difficult prior-year comparison for MACI and expects a larger than typical step up in the third quarter with about 20% year-over-year growth. Vericel expects MACI revenue to grow in the mid to high 30% range for the fourth quarter.
Based on its performance through the early third quarter, Vericel maintained its original guidance of $132 million to $141 million for full-year MACI sales.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
2Q22
2Q21
$ Chg
% Chg
Orthobiologics
$28.6
$26.5
$2.1
7.9%
1H22
1H21
$ Chg
% Chg
Orthobiologics
$54.6
$50.3
$4.3
8.5%
Company Earnings
Amt
% of Sales
Sales
$37.0
Cost of Sales
$14.2
38.3%
General and Admin
$27.1
73.3%
R & D
$0.0
0%
Other
($0.1)
(0.3%)
Net Earnings
($9.0)
(24.2%)
Vericel reported 2Q22 orthopedic sales of $28.6 million, +7.9% vs. 2Q21. The company generated the highest MACI revenue total of any non-4Q since launch.
The company beat a difficult prior-year comparison for MACI and expects a larger than typical step up in the third quarter with about 20% year-over-year growth. Vericel expects MACI...
Vericel reported 2Q22 orthopedic sales of $28.6 million, +7.9% vs. 2Q21. The company generated the highest MACI revenue total of any non-4Q since launch.
The company beat a difficult prior-year comparison for MACI and expects a larger than typical step up in the third quarter with about 20% year-over-year growth. Vericel expects MACI revenue to grow in the mid to high 30% range for the fourth quarter.
Based on its performance through the early third quarter, Vericel maintained its original guidance of $132 million to $141 million for full-year MACI sales.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
2Q22
2Q21
$ Chg
% Chg
Orthobiologics
$28.6
$26.5
$2.1
7.9%
1H22
1H21
$ Chg
% Chg
Orthobiologics
$54.6
$50.3
$4.3
8.5%
Company Earnings
Amt
% of Sales
Sales
$37.0
Cost of Sales
$14.2
38.3%
General and Admin
$27.1
73.3%
R & D
$0.0
0%
Other
($0.1)
(0.3%)
Net Earnings
($9.0)
(24.2%)
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
